Diffuse Intrinsic Pontine Glioma Clinical Trial
Official title:
Phase 1 Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors
This is a Phase 1 study of central nervous system (CNS) locoregional adoptive therapy with SC-CAR4BRAIN, an autologous CD4+ and CD8+ T cells lentivirally transduced to express to express combinations of B7-H3, EGFR806, HER2, and IL13-zetakine chimeric antigen receptors (CAR). CAR T cells are delivered via an indwelling catheter into the ventricular system in children and young adults with diffuse intrinsic pontine glioma (DIPG), diffuse midline glioma (DMG), and recurrent or refractory CNS tumors. A child or young adult meeting all eligibility criteria, including having a CNS catheter placed into their ventricular system, and meeting none of the exclusion criteria will have their T cells collected. The T cells will then be bioengineered into a second-generation CAR T cell that target B7H3, EGFR806, HER2, and IL13-zetakine on tumor cells. Patients will be assigned to 1 of 2 treatment Arms based on the type of their tumor: - Arm A is for patients with DIPG (meaning primary disease localized to the pons, metastatic disease is allowed) anytime after standard radiation OR after progression. - Arm B is for patients with non-pontine DMG (meaning DMG in other parts of the brain such as the thalamus or spine) anytime after standard radiation OR after progression. This Arm also includes other recurrent/refractory CNS tumors.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01922076 -
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
|
Phase 1 | |
| Recruiting |
NCT05476939 -
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
|
Phase 3 | |
| Terminated |
NCT03330197 -
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG
|
Phase 1/Phase 2 | |
| Terminated |
NCT03690869 -
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02992015 -
Gemcitabine in Newly-Diagnosed Diffuse Intrinsic Pontine Glioma
|
Early Phase 1 | |
| Terminated |
NCT01182350 -
Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)
|
Phase 2 | |
| Recruiting |
NCT04837547 -
PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy
|
Phase 1 | |
| Active, not recruiting |
NCT04911621 -
Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06333899 -
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
|
Early Phase 1 | |
| Completed |
NCT00879437 -
Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
|
Phase 2 | |
| Active, not recruiting |
NCT02420613 -
Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma
|
Phase 1 | |
| Completed |
NCT03086616 -
CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With Diffuse Intrinsic Pontine Glioma (DIPG) (PNOC 009)
|
Phase 1 | |
| Recruiting |
NCT01837862 -
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06093165 -
RE-irradiation of Diffuse MIdline Glioma paTients
|
N/A | |
| Withdrawn |
NCT03632317 -
A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas
|
Phase 2 | |
| Completed |
NCT02502708 -
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
|
Phase 1 | |
| Recruiting |
NCT02233049 -
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication
|
Phase 2 | |
| Completed |
NCT00996723 -
Clinical Trial Evaluating the Combination of Vandetanib and Dasatinib During and After Radiation Therapy (RT) in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)
|
Phase 1 | |
| Recruiting |
NCT05009992 -
Combination Therapy for the Treatment of Diffuse Midline Gliomas
|
Phase 2 | |
| Recruiting |
NCT04049669 -
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
|
Phase 2 |